兆科眼科-B(06622.HK) 公布,BRIMOCHOL PF的第II期临床试验已于2025年3月24日入组首名患者。该药为集团候选药物之一,适应症为老花眼。该第II期临床试验为一项多中心、随机、双盲、交叉及安慰剂对照研究。该试验的主要目的为评估该药滴眼液对中国老花眼患者的疗效及安全性。该试验由温州医科大学附属眼视光医院瞿佳教授出任牵头研究者,将涉及14个中心,并入组合共119名患者。董事会同时...
Source Link兆科眼科-B(06622.HK) 公布,BRIMOCHOL PF的第II期临床试验已于2025年3月24日入组首名患者。该药为集团候选药物之一,适应症为老花眼。该第II期临床试验为一项多中心、随机、双盲、交叉及安慰剂对照研究。该试验的主要目的为评估该药滴眼液对中国老花眼患者的疗效及安全性。该试验由温州医科大学附属眼视光医院瞿佳教授出任牵头研究者,将涉及14个中心,并入组合共119名患者。董事会同时...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.